Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Gene Expression of Metalloproteinases, Tissue Inhibitors of Metalloproteinases and Cytokines in Adriamycin-induced Cardiomyopathy

아드리아마이신으로 유도된 심근증에서 Metalloproteinase, Metalloproteinase 조직억제자, Cytokine 유전자 발현에 대한 연구

  • Hong, Young Mi (Department of Pediatrics, College of Medicine, Ewha Womans University)
  • 홍영미 (이화대학교 의과대학 동대문병원 소아과)
  • Received : 2004.09.10
  • Accepted : 2004.10.09
  • Published : 2005.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Changes in metalloproteinases(MMP) activity have been demonstrated in several disease states, including rheumatoid arthritis and tumor metastasis. More importantly, increased myocardial MMP activity has been reported to occur in both clinical and experimental forms of dilated cardiomyopathy. There was no report about MMP in adriamycin(ADR)-induced cardiomyopathy. The purpose of this study was to investigate gene expression of MMP and tissue inhibitor of metalloproteinases(TIMP) in ADR-induced cardiomyopathy and clarify the relationship between MMP and cytokines. Methods : Male Sprague-Dawley rats were divided into two groups. The first group was control. The second group was given intraperitoneal injections of ADR(5 mg/kg) twice a week over two weeks. Serum concentrations of MMP, TIMP, interleukin(IL)-6 and tumor necrosis factor(TNF)-${\alpha}$ were measured. RNA extraction was performed from frozen rat hearts. Reverse transcription polymerase chain reaction(RT-PCR) was employed. cDNA Microarray analysis was performed by using a set of 5,184 sequence-verified rat cDNA clones. Results : Serum MMP and TIMP levels were not significantly different between the two groups. IL-6 was $36.8{\pm}2.8pg/mL$ and TNF-${\alpha}$ $2.2{\pm}2.7pg/mL$ in the ADR group. They were significantly higher than in the control group. Serum MMP correlated significantly with TNF-${\alpha}$(r=0.41, P<0.05). There was no gene expression of MMP, IL-6 or TNF-${\alpha}$ in the hearts of both groups. Gene expression of TIMP was significantly depressed in the hearts of the ADR group. Conclusion : These results suggested a potential role for TNF-${\alpha}$ in the regulation of extracellular matrix remodeling in ADR induced cardiomyopathy. Rapid screening of multiple decreased gene expression by DNA chip may be a useful diagnostic test to detect early cardiac injury before developing ADR induced cardiomyopathy.

목 적 : MMP 활동의 변화는 류마치스 관절염과 암 전위를 비롯한 여러 질환에서 보고되고 있다. 최근에 확장성 심근증에서 MMP 활동의 증가가 발표되었다. 아드리아마이신으로 유도된 심근증에서 MMP에 대한 보고는 없는 실정이다. 아드리아마이신으로 유도된 심근증에서 MMP, TIMP 유전자 발현을 연구하고 cytokine과의 관련성을 알아보고자 본 연구를 실시하였다. 방 법 : Sprague Dawley 쥐에 아드리아마이신 5 mg/kg을 1주일에 2번씩 2주간(누적 용량 : 20 mg/kg) 복강내 주사하였고, 정상쥐를 대조군으로 하였다. 2주 후에 쥐를 희생시켜서 혈청과 심장조직을 얻었다. 혈청에서 ELISA 원리로 MMP-2, TIMP-3, IL-6, TNF-${\alpha}$를 측정하였다. 심장에서 total RNA를 추출하였고, MMP-2, TIMP-3 IL-6, TNF-${\alpha}$ primer를 이용하여 PCR로 증폭하였다. 증폭된 DNA는 1% agarose gel에서 전기 영동하였고 UV light 아래에서 필름으로 촬영하였다. 결 과 : 혈청 MMP-2와 TIMP-3는 두 군 간에 유의한 차이가 없었다. 아드리아마이신군에서 IL-6은 $36.8{\pm}2.8pg/mL$, TNF-${\alpha}$은 $2.2{\pm}2.7pg/mL$로 정상군에 비해 유의한 증가를 보였다. 혈청 MMP-2와 TNF-${\alpha}$와는 r=0.41로 유의한 상관관계가 있었다. 심근 조직에서 MMP-2, IL-6, TNF-${\alpha}$는 발현되지 않았고, TIMP-3는 아드리아마이신군에서 대조군에 비해 유전자 발현이 감소되었다. 결 론 : 아드리아마이신으로 유도된 급성 심근증 모델에서는 심근에서 MMP, IL-6, TNF-${\alpha}$가 발현되지 않았고, TIMP 발현이 감소함을 알 수 있었다. 혈청 MMP와 TNF-${\alpha}$와의 상관성이 유의하게 높았으므로 TNF-${\alpha}$가 MMP 발현을 조절함을 시사해 준다. 앞으로 만성 심근증 모델에서 MMP, TIMP 발현에 대하여 연구할 예정이다.

Keywords

Acknowledgement

Supported by : 이화여자대학교 동대문병원

References

  1. Buzadar AV, Marcus CS, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985;55;2761-5 https://doi.org/10.1002/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P
  2. Kantrowitz ME, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984;27:195-200 https://doi.org/10.1016/0033-0620(84)90004-5
  3. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG. Increased matrix metalloproteinases activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998;97:1708-15 https://doi.org/10.1161/01.CIR.97.17.1708
  4. Weber KT, Pick R, Janicki JS, Gadodia G, Lakier JB. Inadequate collagen tethers in dilated cardiomyopathy. Am Heart J 1988;116:1641-6 https://doi.org/10.1016/0002-8703(88)90763-6
  5. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy : role of metalloproteinases and pyridinoline cross links. Am J Pathol 1996;148:1639-48
  6. Levine J, Kalman L, Mayer H, Fillit H, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41 https://doi.org/10.1056/NEJM199007263230405
  7. Huber SA, Graveline D, Born WK, O'Brien RL. Cytokine production by V$gamma$(＋)-T-cell subsets is an important factor determing CD4＋-Th-cell phenotype and susceptability of BALB/c mice to coxsackievirus B3-induced myocarditis. J Virol 2001;75:5860-9. https://doi.org/10.1128/JVI.75.13.5860-5869.2001
  8. Wada H, Saito K, Kanda T, Kobayashi I, Fujii H, Fujigaki S, et al. Tumor necrosis factor $alpha$(TNF-$alpha$) plays a protective role in acute viral myocarditis in mice. A study using mice lacking TNF-$alpha$. Circulation 2001;103:743-9 https://doi.org/10.1161/01.CIR.103.5.743
  9. Mann DL. Tumor necrosis factor and viral myocarditis : The fine line between innate and inappropriate immune responses in the heart. Circulation 2001;103;626-9 https://doi.org/10.1161/01.CIR.103.5.626
  10. Munger MA, Johnson B, Amber IJ, Callahan KS, Gibert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:723-7 https://doi.org/10.1016/S0002-9149(97)89206-5
  11. Roig E, Orus J, Pare C, Azqueta M, Filella X, Perez-Villa F, et al. Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 1998;82:688-90 https://doi.org/10.1016/S0002-9149(98)00388-9
  12. Munkvad S, Gram J, Jespersen J. Interleukin-1 and tumor necrosis factor-alpha in plasma of patients with acute ischemic heart disease who undergo thrombolytic therapy : a randomized, placebo-controlled study. Lymphokine Cytokine Res 1991;10:325-7
  13. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92:1487-93 https://doi.org/10.1161/01.CIR.92.6.1487
  14. Petretta M, Condorelli GL, Spinelli L, Scopacasa F, De Caterina M, Leosco D, et al. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am Heart J 2000;144:e28
  15. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Ele-vated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41 https://doi.org/10.1056/NEJM199007263230405
  16. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-$alpha$ and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-11 https://doi.org/10.1161/01.CIR.93.4.704
  17. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996;347: 1151-5 https://doi.org/10.1016/S0140-6736(96)90610-8
  18. Henke A, Mohr C, Sprenger H, Graebner C, Stelzner A, Nain M, et al. Coxsackievirus B3-induced production of tumor necrosis factor-$alpha$, IL-1$beta$, and IL-6 in human monocytes. J Immunol 1992;148:2270-7
  19. Satoh M, Tamura G, Segawa I, Tashiro A, Hiramori K, Satodate R. Expression of cytokine genes and presence of enteroviral genomic RNA in endomyocardial biopsy tissues of myocarditis and dilated cardiomyopathy. Virchows Arch 1996;427:503-9
  20. Hong YM, Kim SS. The role of apoptosis in adriamycin induced cardiotoxicity and preventive effect of L-carnitine in rat. Korean J Pediatr 1998;41:760-8
  21. Hong YM, Lim BK, Shin JO, Jeon ES. Change of serum cardiac troponin T and fetal troponin T isoform in rats with adriamycin-induced cardiac injury. Korean Cir J 2002; 32:485-91 https://doi.org/10.4070/kcj.2002.32.6.485
  22. Mann DL. Stress activated cytokines and the heart. Cytokine Growth Factor Rev 1996;7:341-54 https://doi.org/10.1016/S1359-6101(96)00043-3
  23. Eddy LJ, Goeddel DV, Wong GH. Tumor necrosis factor- $alpha$ pretreatment is protective in rat model of myocardial ischemia- perfusion injury. Biochem Biophys Res Comm 1992; 184:1056-9 https://doi.org/10.1016/0006-291X(92)90698-K
  24. Siwik DA, Chang DL, Colucci WS. Interluekin-1 $beta$ and tumor necrosis factor-$alpha$ decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblast in vitro. Cir Res 2000;86:1259-65 https://doi.org/10.1161/01.RES.86.12.1259
  25. Munger MA, Johnson B, Amber IJ, Callahan KS, Gibert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:723-7 https://doi.org/10.1016/S0002-9149(97)89206-5
  26. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391-8
  27. Sharma R, Coats AJ, Anker MD. The role of inflammatory mediators in chronic heart failure : cytokines, nitric oxide, and endothelin-1. Int J Cardiol 2000;72:175-86 https://doi.org/10.1016/S0167-5273(99)00186-2
  28. Kapadia S, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997;81:187-95 https://doi.org/10.1161/01.RES.81.2.187
  29. Niebauer J, Volk HD, Kemp M, Dominguez M, Schmann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure : a prospective cohort study. Lancet 1999;353:1838-42 https://doi.org/10.1016/S0140-6736(98)09286-1
  30. Hasper D, Hummel M, Klebel FX, Reindl I, Volk HD. Systemic inflammation in patients with heart failure. Eur Heart J 1998;19:761-5 https://doi.org/10.1053/euhj.1997.0858
  31. Yamaguchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto Y. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 1995;91:1520-4 https://doi.org/10.1161/01.CIR.91.5.1520
  32. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34 https://doi.org/10.1161/01.CIR.96.2.526
  33. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja K, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular diasease. Circulation 2003;107: 1579-85 https://doi.org/10.1161/01.CIR.0000058700.41738.12
  34. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Cir Res 1995;77:863-8 https://doi.org/10.1161/01.RES.77.5.863
  35. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 1996;155:13-21 https://doi.org/10.1007/BF00714328
  36. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Discordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloprotinase-1 in rheumatoid human synovial fibroblast : synergistic effects of interleukin-1 and tumor necrosis factor-$alpha$ on stromelysin expression. J Biol Chem 1990;265:17238-45
  37. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000;102:1944-9 https://doi.org/10.1161/01.CIR.102.16.1944
  38. Mariadason JM, Augenlicht LH, Arango D. Microarray analysis in the clinical management of cancer. Hematol Oncol Clin North Am 2003;17:377-87 https://doi.org/10.1016/S0889-8588(03)00006-6
  39. Pattern-Hitt E. Gene chips and cancer diagnosis. Nature Med 2001;7:673-79. https://doi.org/10.1038/89044